Selection, Initiates First Site for Phase 2/3 of SIL204 in Pancreatic Cancer
SLXN Silexion Therapeutics Corp
$1.84 +15.00%
차트·분석 보기 → - 1Selection Therapeutics (SLXN) has initiated the Phase 2/3 clinical trial of SIL204 at the Tel Aviv Sourasky Medical Center.
- 2The trial combines standard chemotherapy for patients with locally advanced pancreatic cancer, starting with a safety run-in of approximately 18 patients, followed by expansion to approximately 166 randomized patients.
- 3With the site launch, patient screening can begin within weeks, and the company stated that it has shifted from regulatory preparation to clinical execution.
Ringkasan 3 poin ini disusun dari laporan berikut.
FinanceWire +1 Lihat Sumber Asli ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다